These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9751696)

  • 1. Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART.
    Berger EA; Moss B; Pastan I
    Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11511-3. PubMed ID: 9751696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo testing of anti-HIV immunotoxins.
    Pincus SH; Marcotte TK; Forsyth BM; Fang H
    Methods Mol Biol; 2001; 166():277-94. PubMed ID: 11217373
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques.
    Kennedy PE; Bera TK; Wang QC; Gallo M; Wagner W; Lewis MG; Berger EA; Pastan I
    J Leukoc Biol; 2006 Nov; 80(5):1175-82. PubMed ID: 16923920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it.
    Hamer DH
    Curr HIV Res; 2004 Apr; 2(2):99-111. PubMed ID: 15078175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.
    Wang FX; Xu Y; Sullivan J; Souder E; Argyris EG; Acheampong EA; Fisher J; Sierra M; Thomson MM; Najera R; Frank I; Kulkosky J; Pomerantz RJ; Nunnari G
    J Clin Invest; 2005 Jan; 115(1):128-37. PubMed ID: 15630452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs.
    Sánchez-Duffhues G; Vo MQ; Pérez M; Calzado MA; Moreno S; Appendino G; Muñoz E
    Curr Drug Targets; 2011 Mar; 12(3):348-56. PubMed ID: 20955147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of short-course antenatal antiretroviral therapy on viral load and mother-to-child transmission in subsequent pregnancies among HIV-infected women.
    French CE; Tookey PA; Cortina-Borja M; de Ruiter A; Townsend CL; Thorne C
    Antivir Ther; 2013; 18(2):183-92. PubMed ID: 23475123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of anti-HIV immunotoxins.
    Pincus SH
    Antiviral Res; 1996 Dec; 33(1):1-9. PubMed ID: 8955848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication.
    Dhamija N; Rawat P; Mitra D
    Subcell Biochem; 2013; 61():479-505. PubMed ID: 23150264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy in pregnancy: balancing the risk of preterm delivery with prevention of mother-to-child HIV transmission.
    Townsend CL; Tookey PA; Newell ML; Cortina-Borja M
    Antivir Ther; 2010; 15(5):775-83. PubMed ID: 20710059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic approaches targeting HIV reservoirs].
    Cheret A
    Virologie (Montrouge); 2019 Aug; 23(4):250-259. PubMed ID: 31414662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of maternal HAART on the prevention of mother-to-child transmission of HIV: results of an 18-month follow-up study in Ouagadougou, Burkina Faso.
    Kouanda S; Tougri H; Cisse M; Simpore J; Pietra V; Doulougou B; Ouedraogo G; Ouedraogo CM; Soudre R; Sondo B
    AIDS Care; 2010 Jul; 22(7):843-50. PubMed ID: 20635248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice.
    Goldstein H; Pettoello-Mantovani M; Bera TK; Pastan IH; Berger EA
    J Infect Dis; 2000 Mar; 181(3):921-6. PubMed ID: 10720513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
    Kim Y; Anderson JL; Lewin SR
    Cell Host Microbe; 2018 Jan; 23(1):14-26. PubMed ID: 29324227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant toxins as novel therapeutic agents.
    Pastan I; Chaudhary V; FitzGerald DJ
    Annu Rev Biochem; 1992; 61():331-54. PubMed ID: 1497314
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of HIV-infected pregnant women: prevention of virus transmission and adverse effects in mother and child].
    Boer K; Nellen JF; Kreyenbroek ME; Godfried MH
    Ned Tijdschr Geneeskd; 2009; 153():B410. PubMed ID: 19785876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.
    Palombi L; Marazzi MC; Voetberg A; Magid NA
    AIDS; 2007 Jul; 21 Suppl 4():S65-71. PubMed ID: 17620755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of human immunodeficiency virus-1 latency and its reactivation.
    Verdin E
    Bull Mem Acad R Med Belg; 2008; 163(6):355-64; discussion 364-5. PubMed ID: 19445107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.